首页|碳青霉烯耐药革兰阴性杆菌的耐药机制及抗菌药物的研究进展

碳青霉烯耐药革兰阴性杆菌的耐药机制及抗菌药物的研究进展

扫码查看
碳青霉烯类抗生素是一类非典型的β-内酰胺类药物,是目前抗菌谱最广、杀菌活性最强的抗生素,然而随着此类抗生素的广泛使用,碳青霉烯耐药革兰阴性杆菌(Carbapenem-resistant organism,CRO)在全球范围内扩散,导致临床选择抗菌药物越来越艰难,给临床治疗带来了新的挑战.本文从碳青霉烯酶的产生、通道蛋白的缺失、外排泵的过度表达、药物结合位点的改变、生物膜的形成等5个方面介绍了碳青霉烯类抗生素的耐药机制,以及对抗菌药物的选择进行综述,为临床预防和治疗CRO提供科学依据.
Research Progress on Drug Resistance Mechanism and Antibacterial Drugs of Carbapenem-resistant Gram-negative Bacilli
A class of atypical β-lactam antibiotics with the strongest bactericidal activity and the largest antibacterial spectrum are the carbapenem antibiotics.However,with the widespread use of such antibiotics,Carbapenem-resistant Organisms(CRO)have spread around the world,posing new challenges to the selection of clinical antibiotics.The synthesis of carbapenemase(the most significant),the loss of channel protein,the overexpression of efflux pump,the modification of drug binding sites,and the formation of biofilm are the five features from which the resistance mechanism of carbapenem antibiotics was introduced in this study.In addition,the selection of antibiotics was reviewed to provide a scientific basis for clinical prevention and treatment of CRO

carbapenem antibioticsgram-negative bacillidrug resistance mechanismantibacterial drugstolerancedrug combination

刘洁、赵建平

展开 >

内蒙古医科大学内蒙古临床医学院,呼和浩特 010050

内蒙古自治区人民医院检验科,呼和浩特 010010

碳青霉烯类抗生素 革兰阴性杆菌 耐药机制 治疗药物 耐药性 联合用药

内蒙古自治区自然科学基金项目内蒙古自治区科技计划项目

2017MS08144201702113

2024

国外医药(抗生素分册)
中国医药集团总公司四川抗菌素工业研究所,中国医学科学院医药生物技术研究所

国外医药(抗生素分册)

影响因子:0.852
ISSN:1001-8751
年,卷(期):2024.45(1)
  • 1
  • 14